Medical Oncology LLC
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanson, David
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
SOLARIS, NCT04094688: Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/25
07/25
NCT04137107: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Recruiting
2/3
348
US, RoW
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
02/25
12/25
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting
2/3
10000
US
Screening Platform
SWOG Cancer Research Network, National Cancer Institute (NCI)
Previously Treated Non-Small Cell Lung Cancer
01/29
01/29
A031701, NCT03609216: Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Recruiting
2
271
US
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
02/27
02/29
PCW WF-1802, NCT03963739: Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

Active, not recruiting
N/A
255
US, RoW
Interview, Questionnaire Administration
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
12/24
12/24

Download Options